Moreover, in AD transgenic mouse model, the inhibition of NLRP3 can largely protect memory loss and decrease Aβ deposition, which provides a possibility of AD therapy by targeting NLRP3 inflammasome [109]. Here, NLRP3 is linked to Alzheimer disease.